Choosing the control arm/standard of care in clinical trials

ESMO 2022: Breast and ovarian trial analysis

ESMO 2022: Highlights, commentary and analysis

Ideal duration of androgen deprivation therapy with post-operative radiotherapy for prostate cancer

Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC

ESMO 2022: Renal roundup

Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or poor risk significantly improved PFS vs PBO

Lenvatinib plus pembro for aRCC - update on the CLEAR study

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial

RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy to treat prostate cancer

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer